Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Phase 2

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: PF-05175157

First Posted Date: 2014-02-03

Last Posted Date: 2016-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT02053116

Locations: 🇺🇸
Pfizer Investigational Site, DeLand, Florida, United States

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Phase 1

Completed

Conditions: Clostridium Difficile

Interventions: Biological: C. difficile vaccine with adjuvant
Biological: placebo

First Posted Date: 2014-02-03

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 184

Registration Number: NCT02052726

Locations: 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States
🇺🇸
Carolina Phase I Research, LLC, Raleigh, North Carolina, United States

and more 7 locations

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Phase 1

Terminated

Conditions: Multiple Sclerosis

Interventions: Biological: PF-06342674 0.25 mg/kg
Biological: Placebo
Biological: PF-06342674 6.0 mg/kg
Biological: PF-06342674 1.5 mg/kg

First Posted Date: 2014-01-27

Last Posted Date: 2017-01-16

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT02045732

Locations: 🇺🇸
Albany Advanced Imaging, Albany, New York, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Fallon Wellness Pharmacy, Latham, New York, United States

and more 5 locations

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Phase 1

Completed

Conditions: Hypercholesterolemia

Interventions: Biological: Bococizumab (PF-04950615; RN316)

First Posted Date: 2014-01-23

Last Posted Date: 2019-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 75

Registration Number: NCT02043301

Locations: 🇺🇸
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States
🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸
MRA Clinical Research, LLC, South Miami, Florida, United States

and more 2 locations

Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: palbociclib isethionate (phase 1 and 2 studies)
Drug: palbociclib commercial free base capsule

First Posted Date: 2014-01-22

Last Posted Date: 2014-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT02041273

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: PF-04449913
Drug: LDAC
Drug: Low dose ARA-C (LDAC)
Drug: Daunorubicin
Drug: Azacitidine
Drug: Cytarabine

First Posted Date: 2014-01-17

Last Posted Date: 2025-02-26

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT02038777

Locations: 🇯🇵
Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan
🇯🇵
Kobe University Hospital, Kobe-shi, Hyogo, Japan
🇯🇵
Akita University Hospital, Akita, Japan

and more 6 locations

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Biological: PF-06342674 Dose A
Biological: PF-06342674 Dose B
Biological: PF-06342674 Dose C
Biological: PF-06342674 Dose D

First Posted Date: 2014-01-17

Last Posted Date: 2018-08-03

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT02038764

Locations: 🇺🇸
Duchossois Center for Advanced Medicine, Chicago, Illinois, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 18 locations

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Phase 2

Terminated

Conditions: Breast Neoplasms
BRCA 1 Gene Mutation
BRCA 2 Gene Mutation

Interventions: Drug: talazoparib

First Posted Date: 2014-01-14

Last Posted Date: 2019-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT02034916

Locations: 🇺🇸
Marin Cancer Care, Inc., Greenbrae, California, United States
🇺🇸
UCLA Hematology-Oncology, Santa Monica, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

and more 67 locations

13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Phase 4

Completed

Conditions: Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Interventions: Biological: 13-valent Pneumococcal conjugate vaccine
Procedure: Blood sample collection

First Posted Date: 2014-01-14

Last Posted Date: 2016-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 1200

Registration Number: NCT02034877

Locations: 🇮🇳
S.B.K.S Medical Institute & Research Centre, Vadodara, Gujarat, India
🇮🇳
M.S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India
🇮🇳
Padmashree Dr. D. Y. Patil Medical College, Pune, Maharashtra, India

and more 13 locations

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: PF-06439535
Biological: Avastin

First Posted Date: 2014-01-09

Last Posted Date: 2014-08-15

Lead Sponsor: Pfizer

Target Recruit Count: 102

Registration Number: NCT02031991

Locations: 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy